Hypomethylating agents plus venetoclax in younger acute myeloid leukemia: Meta-analysis of a shifting treatment paradigm - PubMed
6 hours ago
- #hypomethylating agents
- #acute myeloid leukemia
- #venetoclax
- HMA plus venetoclax achieved a pooled complete remission (CR/CRi) rate of 66% in younger AML patients (median age <70).
- The treatment resulted in a 69% MRD-negative rate and a pooled 1-year overall survival of 75%, surpassing historical database cohorts.
- 66% of patients successfully proceeded to HSCT after induction with HMA/venetoclax.
- Meta-regression indicated a trend toward improved survival with decitabine compared to azacitidine in this combination.
- HMA/venetoclax is supported as an effective induction strategy for selected younger AML patients, warranting further comparison with intensive chemotherapy.